Cannabis has long been broadly associated with cognitive deficits. However, in recent years, an increasing number of studies have shown that cannabis may slow the aging process in the brain and potentially halt the development of Alzheimer’s and dementia. While the general public knows primarily of THC and CBD as active components, research results on numerous other compounds have also demonstrated neuroprotective effects.
📑 Inhaltsverzeichnis
Promising Preclinical Evidence for CBN
A 2025 US study showed that CBN can significantly slow the aging process in the mouse brain. Effective treatment methods for cognitive decline in Alzheimer’s remain limited, making research into new alternatives essential. Past studies using cell cultures demonstrated that CBN can influence certain processes in the mitochondria of nerve cells that are directly linked to their proper function.
Mitochondria are essentially the powerhouses of cells, including nerve cells. They produce a molecule called adenosine triphosphate (ATP), which meets the cell’s energy demands. When this process is disrupted, the energy supply is cut off, leading to cellular breakdown. In nerve cells, this is particularly severe, as it can result in cognitive diseases like Alzheimer’s. CBN appears to intervene regulatively in precisely this process. To better understand earlier research findings, the current study examined the effects of CBN on mice that experience accelerated brain aging.
The results showed that CBN could measurably improve both memory and spatial orientation in these mice. Furthermore, an antioxidative effect of CBN was demonstrated. Oxidative stress is another important risk factor in the development of neurodegenerative diseases. Additionally, it was shown that CBN promotes the production of certain proteins responsible for signal transmission between nerve cells. Remarkably, these effects were more pronounced in female mice. The findings were consistent with earlier study results that also provided strong evidence for CBN’s corresponding effects.
Successful Clinical Trial with CBD and THC
While research into CBN’s effects remains in the preclinical phase, human studies with THC and CBD have already demonstrated efficacy against cognitive decline. In December 2025, data from a Phase 2 clinical trial examining the effectiveness of a cannabis extract in Alzheimer’s patients were published. In the Brazilian study, patients aged 60 to 80 years diagnosed with Alzheimer’s-related dementia were examined.
Participants received either a placebo or a combination of THC and CBD over a 26-week period. The cannabinoids were administered orally. A daily dose consisted of 0.35 mg THC and 0.245 mg CBD. After 26 weeks, participants‘ cognitive performance was assessed using a standardized test—the Mini-Mental State Examination (MMSE). This is a test specifically developed to detect cognitive deficits such as those occurring in dementia.
The results: The cannabis group performed significantly better on the test than the placebo group. The cannabis extract treatment was very well tolerated, with no difference observed compared to the placebo group. This study represents the longest human clinical trial to date on cannabis and Alzheimer’s.
Slowed Brain Aging in Cannabis Users
A 2025 British study provided evidence that cannabis consumption may slow aging processes in the human brain. The study analyzed brain scans from over 25,000 people in Great Britain aged 44 to 81 years. Individuals who reported cannabis use showed significant changes in their neurological processes, indicating slowed brain aging.
This effect was demonstrated using a specialized MRI technique that measures connectivity between different brain regions. This technique, also called functional MRI or fMRI, reveals how brain areas communicate at rest. Remarkably, the brain connectivity patterns in cannabis users showed patterns that appeared opposite to normal aging processes. Rather, the brain activity of users resembled a significantly younger brain.
Researchers believe the observed effects are directly related to the endocannabinoid system. This is supported by the distribution of CB1 receptors in specific brain regions. The more interconnected different brain areas were, the higher the density of CB1 receptors in those areas. Researchers emphasized that the endocannabinoid system is directly linked to the aging process and resulting cognitive decline.
Cannabis consumption appears to help suppress certain age-related inflammatory processes in brain cells, counteracting deterioration. Contrary to the persistent claim that cannabis use makes people stupid, thoughtful cannabis use actually seems to promote neuroplasticity—a factor crucial for mental agility well into old age.
Significant Potential in Terpenes
Not only cannabinoids but also terpenes could help counteract the decline of mental abilities. A recent Australian study examined 12 terpenes commonly found in cannabis for their neuroprotective effects. At least in in-vitro experiments, a corresponding effect was demonstrated. The focus was on a specific protein closely linked to the development of Alzheimer’s and similar diseases. The development of Alzheimer’s is significantly promoted by the protein beta-amyloid. Beta-amyloid pathologically accumulates on nerve cells and disrupts communication between them. In common parlance, this is also called „calcification.“
Researchers investigated whether terpenes could block this specific protein and thereby prevent Alzheimer’s development. For this purpose, a cell culture with human nerve cells was prepared to simulate the destructive effects of beta-amyloid and test terpenes‘ impact on this process. The result: The terpenes alpha-pinene and beta-pinene were able to inhibit beta-amyloid activity, thereby reducing deposits on nerve cells. Some neuroprotective effect was also observed with terpinolene.
Independently, another research paper from Brazil, also published in 2025, further underscored the neuroprotective effects of terpenes. The work summarizes multiple research findings on cell cultures and preclinical animal models examining terpene activity. Beyond the previously mentioned effect of pinene against a protein involved in Alzheimer’s, antioxidative and anti-inflammatory effects were also demonstrated. The terpenes linalool, pinene, and eugenol showed antioxidative effects.
Oxidative stress is another important risk factor in neurodegenerative disease development. Beyond antioxidative effects, many terpenes also demonstrate anti-inflammatory properties. Many degenerative processes are ultimately a form of inflammation. Inhibiting this slows degenerative breakdown. A regenerative effect on the extracellular matrix was also demonstrated. The extracellular matrix refers to the space between nerve cells, consisting of a complex network of proteins. Researchers showed that the terpenes linalool, limonene, and nerolidol inhibit certain degenerative enzymes and pro-inflammatory cytokines in this matrix. This way, the integrity of this network between nerve cells can be maintained.
Sources
- MMSE Test Explained: Alzheimer Research Initiative
- Study on Neurological Effects in Users: Research Square 2025
- Scientific Investigation of Terpenes (Part 1): ScienceDirect / NeuroToxicology
- Scientific Investigation of Terpenes (Part 2): ScienceDirect / Biocell 2025
Kanntest du bereits die neuroprotektive Wirkung von Cannabinoiden?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
